{"commentary":{"count":39,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":22,"podcast":9,"youtube":7,"x_video":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05015608\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"SACHI","nct_id":"NCT05015608","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=sachi-nct05015608. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"SACHI","arms":[{"description":"Savolitinib orally once per day (QD) + Osimertinib orally QD,21day cycles (every 3 weeks)","label":"Savolitinib + Osimertinib","type":"EXPERIMENTAL"},{"description":"Pemetrexed combined with platinumon on Day 1 of 21day cycles (every 3 weeks)","label":"Pemetrexed combined with platinum","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2025-08-22","type":"ACTUAL"},"conditions":["Non-small Cell Lung Cancer"],"enrollment":{"count":216,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Savolitinib + Osimertinib","type":"DRUG"},{"name":"Pemetrexed + Cisplatin /Carboplatin","type":"DRUG"}],"last_update":"2026-05-27","lead_sponsor":"Hutchison Medipharma Limited","official_title":"Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Savolitinib + Osimertinib Versus Pemetrexed + Platinum in Treatment of Patients With NSCLC With MET Amplification","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2025-08-22","type":"ACTUAL"},"primary_outcomes":[{"measure":"PFS","timeFrame":"5 months after the last patient enrolled"}],"references":[{"citation":"Lu S, Wang J, Yang N, Lv D, Chen L, Wu L, Li X, Sun L, Yu Y, Jin B, Yang L, Guo Y, Xu H, Yi T, Zeng A, Dong X, Chen J, Wang Z, Niu H, Cheng Y, Pan P, Deng P, Pan H, Min X, Bai J, Liu L, Zhang T, Li J, Fan S, Shi MM, Mok T, Su W; SACHI Study Group. Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2026 Jan 24;407(10526):375-387. doi: 10.1016/S0140-6736(25)01811-2. Epub 2026 Jan 13.","pmid":"41544643","type":"DERIVED"}],"start_date":{"date":"2021-11-22","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification","url":"https://clinicaltrials.gov/study/NCT05015608"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/sachi-nct05015608"}